9 results about "Fucosyltransferase" patented technology

The invention discloses application of 2-fluorofucose in preparation of a medicine for relieving acute kidney injury, and belongs to the technical field of biology. In-vitro cell experiments and animal experiments prove that 2-fluorofucose can inhibit core fucosylation, competitively inhibit the activity of fucosyltransferase, down-regulate the expression of FUT8 and reduce the core fucosylation level in kidney tissues and renal tubular epithelial cells; by inhibiting core fucosylation, effectively reversing EMT phenotypic transformation induced by hypoxia reoxygenation or ischemia reperfusion, up-regulating E-cadherin expression, down-regulating alpha-SMA and Snail expression and reducing cell migration ability, phosphorylation activation of an ERK pathway is remarkably inhibited, and downstream inflammatory factor release and cell injury signal transduction are blocked, so that the ERK pathway can be used for inhibiting ERK pathway phosphorylation activation. The invention provides application of 2-fluorofucose to preparation of a medicine for relieving acute kidney injury. The invention provides a new choice for treating acute kidney injury, has the outstanding advantages of remarkable curative effect, high safety and the like, and has a wide application prospect.

The invention discloses an FUT2 high-expression cell strain as well as application and a method of the FUT2 high-expression cell strain in vaccine quality control, and belongs to the technical field of vaccines. The technical problem to be solved is that a simple and easy-to-operate cell model is lacked in the prior art, and the cell model is used for evaluating the effectiveness of NoV vaccines on the cellular level. According to the key points of the technical scheme, the FUT2 high-expression cell strain is provided, the cell strain is an HEK 293T cell strain (HEK 293T-FUT2-EGFP) with EGFP fluorescence for overexpressing human alpha 1, 2-fucosyltransferase 2 (FUT2), and the cell strain stably expresses H, Lewis b and Lewis y type HBGA antigens; meanwhile, an alternative neutralization experiment of the cell level of the norovirus vaccine based on the cell strain is developed, a basis is provided for interaction research of the norovirus and host cells, and the cell strain has high practical application value.

The invention discloses an engineering bacterium and a method for synthesizing 3 '-sialic acid lactose based on an RIAD-RIDD self-assembled multienzyme compound. The present invention provides a recombinant microorganism for the production of 3 '-sialic acid lactose wherein the recombinant microorganism has (a) enhanced enzymatic activity of CMP-N-acetylneuraminic acid synthetase and / or expression level of coding gene thereof compared to a wild-type microorganism or an original strain; (b) enhancing the enzymatic activity of the alpha-1, 3-fucosyltransferase and / or the expression level of the encoding gene of the alpha-1, 3-fucosyltransferase; and (c) the CMP-N-acetylneuraminic acid synthetase and the [alpha]-1, 3-fucosyltransferase enzyme form a complex. The recombinant microorganism provided by the invention can improve the intermediate channelization efficiency and yield, has improved substrate utilization rate and is strong in universality.

The present application relates to the technical field of fermentation engineering, and particularly relates to a mutant of alpha-1,2-fucosyltransferase and application thereof. The mutant is based on the amino acid sequence of alpha-1,2-fucosyltransferase and comprises any one or more of the following mutations: K125D, A242C, Y269A, P284L or V292L. The present application provides a plurality of mutants of alpha-1,2-fucosyltransferase, which can effectively improve the ability of Escherichia coli to produce 2'-fucosyllactose and inhibit the generation of impurities. The mutant of alpha-1,2-fucosyltransferase provided by the present application can solve the problem of by-product generation in the fermentation process while improving the yield of 2'-fucosyllactose, which has important significance in the field of 2'-fucosyllactose production.

This invention discloses a method for in vitro synthesis of natural H11 glycopeptides from *Haemaphysalis contortus*, belonging to the field of biomedicine. The method includes the following steps: preparing a glycosyl donor compound using sialic acid glycopeptide SGP as a raw material; activating the glycosyl donor to a glycooxazoline; transglycosylation of the glycooxazoline with an H11 glycopeptide chain carrying acetylglucosamine at the N site to obtain the glycopeptide compound; catalyzing the glycopeptide compound with core fucosyltransferase 8, *Haemaphysalis contortus*-derived galactosyltransferase 1, β-1,4-galactosyltransferase, and fucosyltransferase to obtain corresponding glycosyl modifications from the donor, yielding a natural *Haemaphysalis contortus* H11 glycopeptide containing an LDNF structure and a *Gal(β1,4)Fuc* nematode-specific epitope. This invention can accurately mimic the nematode-specific glycosylation modification of natural H11, with high product uniformity, and can provide an antigen source for vaccine development for *Haemaphysalis contortus* disease.

The application belongs to the technical field of biological medicine, and discloses a preparation method and application of an antibody drug conjugate with site-specific glycosyl coupling. The application discloses a recombinant cell containing a nucleic acid molecule encoding trastuzumab, and the FUT8 gene and the B4GALT1 gene are deleted. The application provides a recombinant cell which can efficiently and stably prepare trastuzumab with a uniform A2 glycosylation type. Based on the trastuzumab, 2, 4 or 6 azido groups can be introduced at specific sites of the antibody by using alpha 1, 6-fucosyltransferase and / or beta 1, 4-galactosyltransferase, and a toxin molecule is further connected, so that an antibody conjugate with uniformity and DAR value = 2, DAR value = 4 or DAR value = 6 is prepared.

The invention relates to a construction method and application of high-yield lactyl-N-difucotetraose engineering bacteria, and belongs to the technical field of bioengineering and food biology. According to the method, genes in a GDP-1-fucose synthesis path are combined and regulated in host bacteria by utilizing a synthetic biological means, alpha-1, 2-fucosyltransferase and alpha-1, 3-fucosyltransferase are heterologously expressed on the basis, and then construction of a DFL high-yield strain is realized through modification strategies such as site-specific mutagenesis and random saturated mutation of rate-limiting enzyme. The invention also provides a method for synthesizing a high-added-value product DFL by taking glycerol as a substrate. The method has reference significance for solving the technical bottleneck of the DFL, provides an effective way for industrial production of the DFL, and has relatively high theoretical research value and social and economic benefits.

The present disclosure provides, inter alia, compositions and methods for detecting changes in level of expression of cell-surface Type 2 terminal lactosamines on a population of cultured cells propagated under different conditions. The disclosure also provides compositions and methods for enforcing stably expressed glycans on human cells. In certain embodiments, the compositions and / or methods utilize one or more members of the α(1,3)-fucosyltransferase family. In certain embodiments, glycoengineered CD44 glycosylated product (e.g. HCELL) is stable for at least 48 hours at 4° C., with retained expression after cell cryopreservation.

The present invention relates to an α-1,2-fucosyltransferase and variants thereof, a polynucleotide encoding the α-1,2-fucosyltransferase or variants thereof, a vector comprising the polynucleotide, a host cell expressing the α-1,2-fucosyltransferase or variants thereof, and a method for producing fucosylated oligosaccharides using the α-1,2-fucosyltransferase or variants thereof, or using the host cell.